The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers
Background. Brain metastases (BMs) from digestive cancers are rare; therefore, no optimal treatment modality has been defined. Methods. We retrospectively reviewed the clinical data of 68257 patients with digestive cancers. Propensity score matching (PSM) was used to balance patient backgrounds betw...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2019/1568465 |
id |
doaj-9e90ebac23604c84bf82efd17aabe9d6 |
---|---|
record_format |
Article |
spelling |
doaj-9e90ebac23604c84bf82efd17aabe9d62020-11-24T21:50:07ZengHindawi LimitedJournal of Oncology1687-84501687-84692019-01-01201910.1155/2019/15684651568465The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive CancersJun Dong0Liyan Wu1Fang Wang2Jinsheng Huang3Pili Hu4Bei Zhang5Liang-ping Xia6Department of Intergrated Therapy in Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, East Dong Feng Road, Guangzhou, Guangdong 510060, ChinaDepartment of Clinical Medicine, Sun Yat-Sen University, No. 74, Zhong Shan Er Lu, Guangzhou, Guangdong 510060, ChinaDepartment of Oncology, The First Affiliated Hospital of Sun Yat-Sen University, No. 58, Zhong Shan Er Lu, Guangzhou, Guangdong 510060, ChinaDepartment of Intergrated Therapy in Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, East Dong Feng Road, Guangzhou, Guangdong 510060, ChinaDepartment of Intergrated Therapy in Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, East Dong Feng Road, Guangzhou, Guangdong 510060, ChinaDepartment of Intergrated Therapy in Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, East Dong Feng Road, Guangzhou, Guangdong 510060, ChinaDepartment of Intergrated Therapy in Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, East Dong Feng Road, Guangzhou, Guangdong 510060, ChinaBackground. Brain metastases (BMs) from digestive cancers are rare; therefore, no optimal treatment modality has been defined. Methods. We retrospectively reviewed the clinical data of 68257 patients with digestive cancers. Propensity score matching (PSM) was used to balance patient backgrounds between groups. Survival differences between different treatment modalities were compared. Univariate and multivariate Cox proportional hazards models were performed to identify prognostic factors on overall survival (OS). Results. 270 patients with BM entered the study. In the entire group, the median survival time after diagnosis of brain metastases was 10.25 months (95% CI: 8.41–12.09 months); local treatment could significantly prolong OS (respectively, P<0.01; even after PSM, P<0.01); combination treatment was more effective than single treatment modality (respectively, P<0.01; even after PSM, P<0.01). However, each combination modality was identically effective (P>0.05). When patients were divided into three groups based on 1, 2-3, or more than 3 metastatic lesion(s), same results were identified between local treatment and without local treatment (1 lesion, P<0.01; 2-3 lesions, P<0.01; more than 3 lesions, P<0.01, respectively) and combination and single treatment (P<0.01, P=0.02, P=0.03, respectively). However, there was no difference between different combined treatments (P>0.05). Multivariate analysis revealed that performance status (P<0.01), presence of extracranial metastasis (P=0.04), number of BM (P<0.01), and local treatment for BM (P<0.01) were independent prognostic factors. Conclusions. Regardless of the number of brain lesions, local treatment achieved higher overall survival times than no local treatment, and combination therapy could offer survival benefit to patients as compared with single therapy.http://dx.doi.org/10.1155/2019/1568465 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jun Dong Liyan Wu Fang Wang Jinsheng Huang Pili Hu Bei Zhang Liang-ping Xia |
spellingShingle |
Jun Dong Liyan Wu Fang Wang Jinsheng Huang Pili Hu Bei Zhang Liang-ping Xia The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers Journal of Oncology |
author_facet |
Jun Dong Liyan Wu Fang Wang Jinsheng Huang Pili Hu Bei Zhang Liang-ping Xia |
author_sort |
Jun Dong |
title |
The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers |
title_short |
The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers |
title_full |
The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers |
title_fullStr |
The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers |
title_full_unstemmed |
The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers |
title_sort |
choice of local treatment modalities for patients with brain metastases from digestive cancers |
publisher |
Hindawi Limited |
series |
Journal of Oncology |
issn |
1687-8450 1687-8469 |
publishDate |
2019-01-01 |
description |
Background. Brain metastases (BMs) from digestive cancers are rare; therefore, no optimal treatment modality has been defined. Methods. We retrospectively reviewed the clinical data of 68257 patients with digestive cancers. Propensity score matching (PSM) was used to balance patient backgrounds between groups. Survival differences between different treatment modalities were compared. Univariate and multivariate Cox proportional hazards models were performed to identify prognostic factors on overall survival (OS). Results. 270 patients with BM entered the study. In the entire group, the median survival time after diagnosis of brain metastases was 10.25 months (95% CI: 8.41–12.09 months); local treatment could significantly prolong OS (respectively, P<0.01; even after PSM, P<0.01); combination treatment was more effective than single treatment modality (respectively, P<0.01; even after PSM, P<0.01). However, each combination modality was identically effective (P>0.05). When patients were divided into three groups based on 1, 2-3, or more than 3 metastatic lesion(s), same results were identified between local treatment and without local treatment (1 lesion, P<0.01; 2-3 lesions, P<0.01; more than 3 lesions, P<0.01, respectively) and combination and single treatment (P<0.01, P=0.02, P=0.03, respectively). However, there was no difference between different combined treatments (P>0.05). Multivariate analysis revealed that performance status (P<0.01), presence of extracranial metastasis (P=0.04), number of BM (P<0.01), and local treatment for BM (P<0.01) were independent prognostic factors. Conclusions. Regardless of the number of brain lesions, local treatment achieved higher overall survival times than no local treatment, and combination therapy could offer survival benefit to patients as compared with single therapy. |
url |
http://dx.doi.org/10.1155/2019/1568465 |
work_keys_str_mv |
AT jundong thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT liyanwu thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT fangwang thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT jinshenghuang thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT pilihu thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT beizhang thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT liangpingxia thechoiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT jundong choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT liyanwu choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT fangwang choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT jinshenghuang choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT pilihu choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT beizhang choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers AT liangpingxia choiceoflocaltreatmentmodalitiesforpatientswithbrainmetastasesfromdigestivecancers |
_version_ |
1725885207158980608 |